<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="oil1000/PMC6540057/results/search/disease/results.xml">
  <result pre="to survive. In accordance, PL biosynthetic pathways are up-regulated in" exact="cancer" post="[ 102, 135]. Several alterations in membrane composition and"/>
  <result pre="membrane composition and PL synthesis, distribution, or catabolism reported in" exact="cancer" post="are listed below: PtdIns(3,4,5)P3 concentration is also elevated in"/>
  <result pre="transduction of proliferative signals [ 139]. Other SL involved in" exact="cancer" post="pathology include Cer, Sph and S1P (reviewed in ["/>
  <result pre="an abnormal SL signaling in carcinogenesis of various types of" exact="cancer" post="due to alterations in the activity of enzymes that"/>
  <result pre="of SL [ 144]. Other lipid metabolism genes related with" exact="cancer" post="are Oxidized Low Density Lipoprotein Receptor 1 (OLR1) and"/>
  <result pre="(OLR1) and Glutaredoxin (GLRX), which are upregulated in breast and" exact="prostate cancer" post="tissues [ 145]. The oncogenic antigen-519, a molecular marker"/>
  <result pre="and Glutaredoxin (GLRX), which are upregulated in breast and prostate" exact="cancer" post="tissues [ 145]. The oncogenic antigen-519, a molecular marker"/>
  <result pre="[ 145]. The oncogenic antigen-519, a molecular marker found in" exact="breast cancer" post="patients with poor prognosis, was identified as FA Synthase"/>
  <result pre="145]. The oncogenic antigen-519, a molecular marker found in breast" exact="cancer" post="patients with poor prognosis, was identified as FA Synthase"/>
  <result pre="sterol regulatory element-binding protein 1 (SREBP1), are highly expressed in" exact="breast cancer" post="tumors and associated with low patient survival [ 147]"/>
  <result pre="regulatory element-binding protein 1 (SREBP1), are highly expressed in breast" exact="cancer" post="tumors and associated with low patient survival [ 147]"/>
  <result pre="multiple signaling events within tumors [ 151]. ▪ Interaction of" exact="cancer" post="cells with components of the tumor stroma: This is"/>
  <result pre="upon prostaglandin presence [ 155]. ▪ Lipid metabolic reprogramming in" exact="cancer" post="cells: cancer cells display an enlarged metabolic inventory that"/>
  <result pre="presence [ 155]. ▪ Lipid metabolic reprogramming in cancer cells:" exact="cancer" post="cells display an enlarged metabolic inventory that allows the"/>
  <result pre="survive and grow in the severe tumor environment. Highly proliferative" exact="cancer" post="cells display a strong lipid and Chol avidity, which"/>
  <result pre="or increasing their endogenous synthesis. Excessive lipids and cholesterol in" exact="cancer" post="cells stored in lipid droplets are considered marks of"/>
  <result pre="cancer cells stored in lipid droplets are considered marks of" exact="cancer" post="aggressiveness (reviewed in [ 156]). 5.2. Metabolic Diseases Several"/>
  <result pre="on the molecular mechanism behind the onset of lipid imbalance-driven" exact="obesity" post="and diabetes, both lipid homeostasis and physical principles governing"/>
  <result pre="the membranes are involved. Two examples illustrate this mechanism in" exact="liver disease" post="(reviewed in [ 17]). The liver is a crucial"/>
  <result pre="might lead to dyslipidemia, insulin resistance, type II diabetes, and" exact="obesity" post="[ 163]. ▪ A second example involves the previously"/>
  <result pre="(PPAR-γ) signaling [ 165]. In obese animals, TFEB overexpression rescues" exact="obesity" post="and associated metabolic syndrome by promoting lipophagy [ 166]."/>
  <result pre="165]. In obese animals, TFEB overexpression rescues obesity and associated" exact="metabolic syndrome" post="by promoting lipophagy [ 166]. A high fat diet"/>
  <result pre="[ 101]). 5.4. Immunological Disorders Anti-phospholipid syndrome (APS) is an" exact="autoimmune disease" post="caused by the appearance of anti-PL antibodies and developed"/>
  <result pre="treatment of cancer, parasite causing diseases, viral and bacterial infections," exact="multiple sclerosis" post="or progeria [ 173]. Proteins involved in signal transduction"/>
  <result pre="parasite causing diseases, viral and bacterial infections, multiple sclerosis or" exact="progeria" post="[ 173]. Proteins involved in signal transduction pathways require"/>
  <result pre="(FTIs) were used to inhibit the farnesylation of proteins in" exact="cancer" post="cells. FTIs promoted apoptosis, cell cycle arrest (mainly mitotic"/>
  <result pre="SMS and other enzymes from SL metabolism are altered in" exact="cancer" post="and consequently modify membrane composition and structure. Hydroxyl-C18 unsaturated"/>
  <result pre="the transduction through proliferative signaling cascades and preventing proliferation in" exact="cancer" post="cells [ 139]. Direct MLT-drug binding to a protein"/>
  <result pre="which prevent Ras from binding to membrane and subsequently inhibit" exact="cancer" post="cell proliferation while inducing cell differentiation and cell death"/>
  <result pre="product, SM, and decreasing its substrate PtdEtn in membranes of" exact="cancer" post="cells but not of healthy cells because of the"/>
  <result pre="trials. It has shown good pharmaceutical efficacy and safety against" exact="cancer" post="in humans (ClinicalTrials.gov identifier #NCT01792310). After a first-in-man phase"/>
  <result pre="first-in-man phase I/IIA trial in patients with solid tumors, 43%" exact="glioma" post="patients responded to treatment, although this percentage almost doubled"/>
  <result pre="to membrane and inhibits the Akt/mTORC1 axis and induces specific" exact="cancer" post="cell autophagy [ 209]. Hydroxytriolein is a triacylglycerol mimetic"/>
  <result pre="triacylglycerol mimetic synthetic lipid analogue of triolein shown to block" exact="cancer" post="cell growth in vitro through the β-catenin pathway, downregulation"/>
  <result pre="Xenical ®), a FASN inhibitor administered in the treatment of" exact="breast cancer" post="[ 211]; and ABC294640, a sphingosine kinase 2 and"/>
  <result pre="®), a FASN inhibitor administered in the treatment of breast" exact="cancer" post="[ 211]; and ABC294640, a sphingosine kinase 2 and"/>
  <result pre="use of dietary lipids for the treatment of diabetes or" exact="obesity" post="is a clear case of MLT. For example, body"/>
  <result pre="efficacy of the lipid interacting hydroxylamine derivative arimoclomol in familial" exact="amyotrophic lateral sclerosis." post="Other conditions that are bound to be ameliorated using"/>
  <result pre="retinopathies, nephropathies, acetaminophen liver toxicity, sunburn, ischemia reperfusion, intracranial hemorrhage," exact="atrial fibrillation," post="vascular hypertension damage, and myocardial infarction as reviewed in"/>
  <result pre="eukaryotic common ancestor Lo Liquid-ordered LPA lysoPA LPC lysoPtdCho LSD" exact="lysosomal storage disease" post="LTP lipid transfer protein LUCA last universal common ancestor"/>
  <result pre="A. Hooked on fat: the role of lipid synthesis in" exact="cancer" post="metabolism and tumour development Dis. Model. Mech. 2013 6"/>
  <result pre="Ding Z. et al. P53 and Pten control neural and" exact="glioma" post="stem/progenitor cell renewal and differentiation Nature 2008 455 1129"/>
  <result pre="Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of" exact="glioma" post="cells and in 2-hydroxyoleic acid therapy Proc. Natl. Acad."/>
  <result pre="et al. 2-Hydroxyoleate, a nontoxic membrane binding anticancer drug, induces" exact="glioma" post="cell differentiation and autophagy Proc. Natl. Acad. Sci. USA"/>
  <result pre="22586083 140. Furuya H. Shimizu Y. Kawamori T. Sphingolipids in" exact="cancer" post="Cancer Metastasis Rev. 2011 30 567 576 10.1007/s10555-011-9304-1 22005951"/>
  <result pre="Moreno V. Genetic polymorphisms in fatty acid metabolism genes and" exact="colorectal cancer" post="Mutagenesis 2012 27 169 176 10.1093/mutage/ger066 22294764 149. Dielschneider"/>
  <result pre="V. Genetic polymorphisms in fatty acid metabolism genes and colorectal" exact="cancer" post="Mutagenesis 2012 27 169 176 10.1093/mutage/ger066 22294764 149. Dielschneider"/>
  <result pre="Hwang D. Suh P.-G. Ryu S.H. Phospholipase signalling networks in" exact="cancer" post="Nat. Rev. Cancer 2012 12 782 792 10.1038/nrc3379 23076158"/>
  <result pre="Beloribi-Djefaflia S. Vasseur S. Guillaumond F. Lipid metabolic reprogramming in" exact="cancer" post="cells Oncogenesis 2016 5 e189 10.1038/oncsis.2015.49 26807644 157. Reference"/>
  <result pre="metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in" exact="obesity" post="Nature 2011 473 528 531 10.1038/nature09968 21532591 165. Lin"/>
  <result pre="Berndt N. Hamilton A.D. Sebti S.M. Targeting protein prenylation for" exact="cancer" post="therapy Nat. Rev. Cancer 2011 11 775 791 10.1038/nrc3151"/>
  <result pre="Ochocki J.D. Distefano M.D. Prenyltransferase inhibitors: treating human ailments from" exact="cancer" post="to parasitic infections Med. Chem. Commun. 2013 4 476"/>
  <result pre="Villa-Pulgarin J.A. Campanero M.A. Blanco-Prieto M.J. Lipid raft-targeted therapy in" exact="multiple myeloma" post="Oncogene 2010 29 3748 3757 10.1038/onc.2010.131 20418917 194. Bäumer"/>
  <result pre="reduction in local inflammation by a lipid raft molecule in" exact="atopic dermatitis" post="Allergy 2010 65 1158 1165 10.1111/j.1398-9995.2010.02341.x 20337610 196. Lladó"/>
  <result pre="in local inflammation by a lipid raft molecule in atopic" exact="dermatitis" post="Allergy 2010 65 1158 1165 10.1111/j.1398-9995.2010.02341.x 20337610 196. Lladó"/>
  <result pre="M. Soriano J.B. Escribá P.V. Busquets X. Regulation of the" exact="cancer" post="cell membrane lipid composition by NaCHOleate Biochim. Biophys. Acta"/>
  <result pre="Antitumoral actions of the anti-obesity drug orlistat (Xenical TM) in" exact="breast cancer" post="cells: blockade of cell cycle progression, promotion of apoptotic"/>
  <result pre="actions of the anti-obesity drug orlistat (Xenical TM) in breast" exact="cancer" post="cells: blockade of cell cycle progression, promotion of apoptotic"/>
 </snippets>
</snippetsTree>
